Aperture Sectors › Healthcare & Life Sciences › Drug discovery & protein design
Drug discovery & protein design funding
Drug discovery & protein design
A sub-sector of Healthcare & Life Sciences. Each company counts once, in its main sub-sector.
262 rounds, $14.4B raised by 208 companies, Jan 2, 2023 to Nov 14, 2026, 31% of Healthcare & Life Sciences capital. Top three companies: Isomorphic Labs 19%, Xaira Therapeutics 7%, SandboxAQ 6%.
| Company | HQ | Capital raised | Rounds | Exit |
|---|---|---|---|---|
| Isomorphic Labs | United Kingdom | $2.7B | 2 | — |
| Xaira Therapeutics | United States | $1B | 1 | — |
| SandboxAQ | United States | $800M | 3 | — |
| Enveda | United States | $697M | 6 | — |
| NewLimit | United States | $605M | 3 | — |
| Chai Discovery | United States | $600M | 3 | — |
| Eikon Therapeutics | United States | $457M | 2 | — |
| Generate:Biomedicines | United States | $273M | 1 | Listed |
| Kardigan | United States | $254M | 1 | — |
| Iambic Therapeutics | United States | $250M | 3 | — |
| Syneron | China | $250M | 2 | — |
| Genesis Therapeutics | United States | $240M | 2 | — |
| Warp Sciences | United States | $215M | 1 | — |
| Superluminal Medicines | United States | $213M | 3 | — |
| Basecamp Research | United Kingdom | $200M | 2 | — |
| Soley Therapeutics | United States | $200M | 1 | — |
| Asimov | United States | $175M | 1 | — |
| Outpace Bio | United States | $144M | 1 | — |
| Profluent | United States | $141M | 2 | — |
| Aureka Biotechnologies (寻明生科) | China | $135M | 2 | — |
| Alterome Therapeutics | United States | $132M | 1 | — |
| Seismic Therapeutic | United States | $121M | 1 | — |
| Terray Therapeutics | United States | $120M | 1 | — |
| Insilico Medicine | United States | $110M | 1 | Listed |
| Alltrna | United States | $109M | 1 | — |
| Company | Amount | Stage | Announced |
|---|---|---|---|
| Isomorphic Labs | $2.1B | Series B | May 12, 2026 |
| Xaira Therapeutics | $1B | Unlabeled | Apr 24, 2024 |
| Isomorphic Labs | $600M | Unlabeled | Mar 31, 2025 |
| SandboxAQ | $500M | Series D | Feb 14, 2023 |
| NewLimit | $435M | Series C | Jun 2, 2026 |
| Chai Discovery | $400M | Series C | Jul 14, 2026 |
| Eikon Therapeutics | $351M | Series D | Feb 26, 2025 |
| Enveda | $311M | Series E | Sep 23, 2026 |
| SandboxAQ | $300M | Series E | Dec 18, 2024 |
| Generate:Biomedicines | $273M | Series C | Sep 14, 2023 |